Back to Search Start Over

Expanding the Clinical and Immunological Phenotypes and Natural History of MALT1 Deficiency.

Authors :
Sefer, Asena Pinar
Abolhassani, Hassan
Ober, Franziska
Kayaoglu, Basak
Bilgic Eltan, Sevgi
Kara, Altan
Erman, Baran
Surucu Yilmaz, Naz
Aydogmus, Cigdem
Aydemir, Sezin
Charbonnier, Louis-Marie
Kolukisa, Burcu
Azizi, Gholamreza
Delavari, Samaneh
Momen, Tooba
Aliyeva, Simuzar
Kendir Demirkol, Yasemin
Tekin, Saban
Kiykim, Ayca
Baser, Omer Faruk
Source :
Journal of Clinical Immunology; Apr2022, Vol. 42 Issue 3, p634-652, 19p
Publication Year :
2022

Abstract

Purpose: MALT1 deficiency is a combined immune deficiency characterized by recurrent infections, eczema, chronic diarrhea, and failure to thrive. Clinical and immunological characterizations of the disease have not been previously reported in large cohorts. We sought to determine the clinical, immunological, genetic features, and the natural history of MALT-1 deficiency. Methods: The clinical findings and treatment outcomes were evaluated in nine new MALT1-deficient patients. Peripheral lymphocyte subset analyses, cytokine secretion, and proliferation assays were performed. We also analyzed ten previously reported patients to comprehensively evaluate genotype/phenotype correlation. Results: The mean age of patients and disease onset were 33 ± 17 and 1.6 ± 0.7 months, respectively. The main clinical findings of the disease were recurrent infections (100%), skin involvement (100%), failure to thrive (100%), oral lesions (67%), chronic diarrhea (56%), and autoimmunity (44%). Eosinophilia and high IgE were observed in six (67%) and two (22%) patients, respectively. The majority of patients had normal T and NK cells, while eight (89%) exhibited reduced B cells. Immunoglobulin replacement and antibiotics prophylaxis were mostly ineffective in reducing the frequency of infections and other complications. One patient received hematopoietic stem cell transplantation (HSCT) and five patients died as a complication of life-threatening infections. Analyzing this cohort with reported patients revealed overall survival in 58% (11/19), which was higher in patients who underwent HSCT (P = 0.03). Conclusion: This cohort provides the largest analysis for clinical and immunological features of MALT1 deficiency. HSCT should be offered as a curative therapeutic option for all patients at the early stage of life. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
02719142
Volume :
42
Issue :
3
Database :
Complementary Index
Journal :
Journal of Clinical Immunology
Publication Type :
Academic Journal
Accession number :
156398525
Full Text :
https://doi.org/10.1007/s10875-021-01191-4